Medipharm Labs Corp Stock Fundamentals
| LABS Stock | CAD 0.07 0.01 7.14% |
Medipharm Labs Corp fundamentals help investors to digest information that contributes to Medipharm Labs' financial success or failures. It also enables traders to predict the movement of Medipharm Stock. The fundamental analysis module provides a way to measure Medipharm Labs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medipharm Labs stock.
At this time, Medipharm Labs' Gross Profit is very stable compared to the past year. As of the 28th of November 2024, Cost Of Revenue is likely to grow to about 35 M, while Interest Expense is likely to drop about 346.8 K. Medipharm | Select Account or Indicator |
Medipharm Labs Corp Company Return On Asset Analysis
Medipharm Labs' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Medipharm Labs Return On Asset | -0.0717 |
Most of Medipharm Labs' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medipharm Labs Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medipharm Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Medipharm Labs is extremely important. It helps to project a fair market value of Medipharm Stock properly, considering its historical fundamentals such as Return On Asset. Since Medipharm Labs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medipharm Labs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medipharm Labs' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Medipharm Total Assets
Total Assets |
|
Based on the latest financial disclosure, Medipharm Labs Corp has a Return On Asset of -0.0717. This is 99.18% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on asset for all Canada stocks is 48.79% lower than that of the firm.
Medipharm Labs Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medipharm Labs's current stock value. Our valuation model uses many indicators to compare Medipharm Labs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medipharm Labs competition to find correlations between indicators driving Medipharm Labs's intrinsic value. More Info.Medipharm Labs Corp is currently regarded as number one stock in return on equity category among its peers. It is rated second overall in return on asset category among its peers . At this time, Medipharm Labs' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medipharm Labs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medipharm Labs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Medipharm Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medipharm Labs' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medipharm Labs could also be used in its relative valuation, which is a method of valuing Medipharm Labs by comparing valuation metrics of similar companies.Medipharm Labs is currently under evaluation in return on asset category among its peers.
Medipharm Labs Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medipharm Labs from analyzing Medipharm Labs' financial statements. These drivers represent accounts that assess Medipharm Labs' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medipharm Labs' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 463.2M | 73.4M | 46.2M | 19.4M | 23.6M | 22.4M | |
| Enterprise Value | 435.2M | 72.0M | 12.3M | (4.1M) | 7.9M | 7.5M |
Medipharm Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0717 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 14.28 M | ||||
| Shares Outstanding | 411.12 M | ||||
| Shares Owned By Insiders | 4.45 % | ||||
| Shares Owned By Institutions | 0.71 % | ||||
| Number Of Shares Shorted | 252.82 K | ||||
| Price To Earning | 172.00 X | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 0.71 X | ||||
| Revenue | 33.06 M | ||||
| Gross Profit | (13.42 M) | ||||
| EBITDA | (16.35 M) | ||||
| Net Income | (13.08 M) | ||||
| Cash And Equivalents | 24.14 M | ||||
| Cash Per Share | 0.20 X | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 3.19 X | ||||
| Book Value Per Share | 0.13 X | ||||
| Cash Flow From Operations | (11.76 M) | ||||
| Short Ratio | 1.31 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 0.1 | ||||
| Number Of Employees | 166 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 26.72 M | ||||
| Total Asset | 63.94 M | ||||
| Retained Earnings | (176.73 M) | ||||
| Working Capital | 25.77 M | ||||
| Net Asset | 63.94 M |
About Medipharm Labs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medipharm Labs Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medipharm Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medipharm Labs Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 112 K | 106.4 K | |
| Total Revenue | 33.1 M | 39.7 M | |
| Cost Of Revenue | 28.8 M | 35 M | |
| Stock Based Compensation To Revenue | 0.06 | 0.12 | |
| Sales General And Administrative To Revenue | 0.65 | 0.50 | |
| Research And Ddevelopement To Revenue | 0.01 | 0.01 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.09 | 0.09 | |
| Ebit Per Revenue | (0.55) | (0.58) |
Pair Trading with Medipharm Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medipharm Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.